Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Rating) – Stock analysts at William Blair lifted their Q3 2022 earnings per share estimates for Axsome Therapeutics in a research note issued to investors on Tuesday, April 19th. William Blair analyst M. Minter now expects that the company will earn ($1.01) per share for the quarter, up from their prior forecast of ($1.04). William Blair also issued estimates for Axsome Therapeutics’ Q4 2022 earnings at ($0.87) EPS and FY2022 earnings at ($3.73) EPS.
Axsome Therapeutics (NASDAQ:AXSM – Get Rating) last issued its earnings results on Tuesday, March 1st. The company reported ($0.90) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.99) by $0.09. During the same quarter in the prior year, the firm posted ($0.78) earnings per share.
Shares of NASDAQ:AXSM opened at $39.60 on Friday. Axsome Therapeutics has a 12 month low of $19.38 and a 12 month high of $74.10. The stock has a market cap of $1.52 billion, a price-to-earnings ratio of -11.41 and a beta of 2.41. The stock’s 50 day moving average price is $34.75 and its 200 day moving average price is $34.53. The company has a debt-to-equity ratio of 3.14, a current ratio of 3.75 and a quick ratio of 3.75.
Hedge funds have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC acquired a new stake in shares of Axsome Therapeutics in the 3rd quarter valued at $1,558,000. Two Sigma Investments LP acquired a new position in Axsome Therapeutics during the 3rd quarter worth $699,000. Tudor Investment Corp Et Al lifted its position in Axsome Therapeutics by 238.8% during the 3rd quarter. Tudor Investment Corp Et Al now owns 90,329 shares of the company’s stock worth $2,977,000 after acquiring an additional 63,668 shares during the last quarter. Kaizen Financial Strategies acquired a new position in Axsome Therapeutics during the 3rd quarter worth $247,000. Finally, Citigroup Inc. lifted its position in Axsome Therapeutics by 518.2% during the 3rd quarter. Citigroup Inc. now owns 46,871 shares of the company’s stock worth $1,545,000 after acquiring an additional 39,289 shares during the last quarter. 48.45% of the stock is owned by institutional investors and hedge funds.
About Axsome Therapeutics (Get Rating)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation.
- Get a free copy of the StockNews.com research report on Axsome Therapeutics (AXSM)
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- MarketBeat Podcast: 3 Stocks Flashing Buy Signals
- Should You Buy Carvana or AutoNation or Pass on Both?
- What Should Investors Take Away From Boston Beer’s Earnings?
- High-Yield Kinder Morgan Is Still A Buy
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.